{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T00:57:52Z","timestamp":1795222672058,"version":"4.10.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Headache Federation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s10194-018-0921-8","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T11:30:42Z","timestamp":1537961442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4810-4998","authenticated-orcid":false,"given":"Lars","family":"Bendtsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimos","family":"Mitsikostas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayyaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,26]]},"reference":[{"key":"921_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","volume":"30","author":"JL Natoli","year":"2010","unstructured":"Natoli JL, Manack A, Dean B et al (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30:599\u2013609","journal-title":"Cephalalgia"},{"key":"921_CR2","first-page":"1","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1\u2013211","journal-title":"Cephalalgia"},{"key":"921_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpain.2014.11.004","volume":"16","author":"DW Dodick","year":"2015","unstructured":"Dodick DW, Turkel CC, DeGryse RE et al (2015) Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. J Pain 16:164\u2013175","journal-title":"J Pain"},{"key":"921_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793\u2013803","journal-title":"Cephalalgia"},{"key":"921_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804\u2013814","journal-title":"Cephalalgia"},{"key":"921_CR6","volume-title":"Botulinum toxin type A for the prevention of headaches in adults with chronic migraine","author":"NICE technology appraisal guidance 260","year":"2012","unstructured":"NICE technology appraisal guidance 260 (2012) Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. Available from https:\/\/www.nice.org.uk\/guidance\/ta260"},{"key":"921_CR7","first-page":"1003","volume":"11","author":"R Gooriah","year":"2015","unstructured":"Gooriah R, Ahmed F (2015) OnabotulinumtoxinA for chronic migraine: a critical appraisal. Ther Clin Risk Manag 11:1003\u20131013","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"921_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/ane.12906","volume":"137","author":"T. P. Do","year":"2018","unstructured":"Do TP, Hvedstrup J, Schytz HW (2018) Botulinum toxin: a review of the mode of action in migraine. Acta Neurol Scand 137:442\u2013451","journal-title":"Acta Neurologica Scandinavica"},{"key":"921_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pain.2008.10.005","volume":"141","author":"P Gazerani","year":"2009","unstructured":"Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L (2009) Subcutaneous botulinum toxin type a reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 141:60\u201369","journal-title":"Pain"},{"key":"921_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/ene.12043","volume":"20","author":"MA Leone","year":"2013","unstructured":"Leone MA, Brainin M, Boon P, Pugliatti M, Keindl M, Bassetti CL (2013) Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2012. Eur J Neurol 20:410\u2013419","journal-title":"Eur J Neurol"},{"key":"921_CR11","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921\u2013936","journal-title":"Headache"},{"key":"921_CR12","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","volume":"86","author":"SD Silberstein","year":"2015","unstructured":"Silberstein SD, Dodick DW, Aurora SK et al (2015) Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry 86:996\u20131001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"921_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-017-0784-4","volume":"18","author":"M Matharu","year":"2017","unstructured":"Matharu M, Halker R, Pozo-Rosich P, Degryse R, Manack AA, Aurora SK (2017) The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. J Headache Pain 18:78","journal-title":"J Headache Pain"},{"key":"921_CR14","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0333102416652092","volume":"36","author":"RB Lipton","year":"2016","unstructured":"Lipton RB, Rosen NL, Ailani J, DeGryse RE, Gillard PJ, Varon SF (2016) OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program. Cephalalgia 36:899\u2013908","journal-title":"Cephalalgia"},{"key":"921_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/ane.12171","volume":"129","author":"SK Aurora","year":"2014","unstructured":"Aurora SK, Dodick DW, Diener HC et al (2014) OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand 129:61\u201370","journal-title":"Acta Neurol Scand"},{"key":"921_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","volume":"331","author":"SD Silberstein","year":"2013","unstructured":"Silberstein SD, Blumenfeld AM, Cady RK et al (2013) OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 331:48\u201356","journal-title":"J Neurol Sci"},{"key":"921_CR17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0333102415593088","volume":"36","author":"CC Chiang","year":"2016","unstructured":"Chiang CC, Schwedt TJ, Wang SJ, Dodick DW (2016) Treatment of medication-overuse headache: a systematic review. Cephalalgia 36:371\u2013386","journal-title":"Cephalalgia"},{"key":"921_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1186\/s40064-015-1386-8","volume":"4","author":"F Ahmed","year":"2015","unstructured":"Ahmed F, Zafar HW, Buture A, Khalil M (2015) Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse. Springerplus 4:589","journal-title":"Springerplus"},{"key":"921_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/ene.12393","volume":"21","author":"HC Diener","year":"2014","unstructured":"Diener HC, Dodick DW, Turkel CC et al (2014) Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol 21:851\u2013859","journal-title":"Eur J Neurol"},{"key":"921_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1526-4610.2005.05066.x","volume":"45","author":"NT Mathew","year":"2005","unstructured":"Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C (2005) Botulinum toxin type a (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45:293\u2013307","journal-title":"Headache"},{"key":"921_CR21","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.4065\/80.9.1126","volume":"80","author":"SD Silberstein","year":"2005","unstructured":"Silberstein SD, Stark SR, Lucas SM, Christie SN, DeGryse RE, Turkel CC (2005) Botulinum toxin type a for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 80:1126\u20131137","journal-title":"Mayo Clin Proc"},{"key":"921_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-017-0723-4","volume":"18","author":"EI Aydinlar","year":"2017","unstructured":"Aydinlar EI, Dikmen PY, Kosak S, Kocaman AS (2017) OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study. J Headache Pain 18:23","journal-title":"J Headache Pain"},{"key":"921_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","volume":"19","author":"AM Blumenfeld","year":"2018","unstructured":"Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack AA (2018) Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 19:13","journal-title":"J Headache Pain"},{"key":"921_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/IJGM.S70456","volume":"8","author":"GP Boudreau","year":"2015","unstructured":"Boudreau GP, Grosberg BM, McAllister PJ, Lipton RB, Buse DC (2015) Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. Int J Gen Med 8:79\u201386","journal-title":"Int J Gen Med"},{"key":"921_CR25","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s10072-016-2662-2","volume":"37","author":"C Butera","year":"2016","unstructured":"Butera C, Colombo B, Bianchi F et al (2016) Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type a? Neurol Sci 37:1701\u20131706","journal-title":"Neurol Sci"},{"key":"921_CR26","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s10072-016-2665-z","volume":"37","author":"BE Demiryurek","year":"2016","unstructured":"Demiryurek BE, Ertem DH, Tekin A, Ceylan M, Aras YG, Gungen BD (2016) Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine. Neurol Sci 37:1779\u20131784","journal-title":"Neurol Sci"},{"key":"921_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/head.13211","volume":"58","author":"C Dominguez","year":"2018","unstructured":"Dominguez C, Vieites-Prado A, Perez-Mato M et al (2018) CGRP and PTX3 as predictors of efficacy of Onabotulinumtoxin type a in chronic migraine: an observational study. Headache 58:78\u201387","journal-title":"Headache"},{"key":"921_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/ene.13523","volume":"25","author":"C Dominguez","year":"2018","unstructured":"Dominguez C, Pozo-Rosich P, Torres-Ferrus M et al (2018) OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur J Neurol 25:411\u2013416","journal-title":"Eur J Neurol"},{"issue":"Suppl 1","key":"921_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10072-014-1739-z","volume":"35","author":"L Grazzi","year":"2014","unstructured":"Grazzi L, Usai S (2014) Botulinum toxin a: a new option for treatment of chronic migraine with medication overuse. Neurol Sci 35(Suppl 1):37\u201339","journal-title":"Neurol Sci"},{"key":"921_CR30","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1129-2377-15-54","volume":"15","author":"M Khalil","year":"2014","unstructured":"Khalil M, Zafar HW, Quarshie V, Ahmed F (2014) Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. J Headache Pain 15:54","journal-title":"J Headache Pain"},{"key":"921_CR31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00702-016-1539-0","volume":"123","author":"K Kollewe","year":"2016","unstructured":"Kollewe K, Escher CM, Wulff DU et al (2016) Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm 123:533\u2013540","journal-title":"J Neural Transm"},{"key":"921_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jns.2016.01.054","volume":"363","author":"MJ Lee","year":"2016","unstructured":"Lee MJ, Lee C, Choi H, Chung CS (2016) Factors associated with favorable outcome in botulinum toxin a treatment for chronic migraine: a clinic-based prospective study. J Neurol Sci 363:51\u201354","journal-title":"J Neurol Sci"},{"key":"921_CR33","first-page":"196","volume":"8","author":"B Naderinabi","year":"2017","unstructured":"Naderinabi B, Saberi A, Hashemi M et al (2017) Acupuncture and botulinum toxin a injection in the treatment of chronic migraine: a randomized controlled study. Caspian J Intern Med 8:196\u2013204","journal-title":"Caspian J Intern Med"},{"key":"921_CR34","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1186\/s40064-015-1636-9","volume":"4","author":"A Negro","year":"2015","unstructured":"Negro A, Curto M, Lionetto L, Crialesi D, Martelletti P (2015) OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. Springerplus 4:826","journal-title":"Springerplus"},{"key":"921_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-016-0591-3","volume":"17","author":"A Negro","year":"2016","unstructured":"Negro A, Curto M, Lionetto L, Martelletti P (2016) A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain 17:1","journal-title":"J Headache Pain"},{"key":"921_CR36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s40064-015-0957-z","volume":"4","author":"MI Pedraza","year":"2015","unstructured":"Pedraza MI, de la Cruz C, Ruiz M et al (2015) OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. Springerplus 4:176","journal-title":"Springerplus"},{"key":"921_CR37","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s10072-016-2568-z","volume":"37","author":"M Russo","year":"2016","unstructured":"Russo M, Manzoni GC, Taga A et al (2016) The use of onabotulinum toxin a (Botox((R))) in the treatment of chronic migraine at the Parma headache Centre: a prospective observational study. Neurol Sci 37:1127\u20131131","journal-title":"Neurol Sci"},{"key":"921_CR38","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3389\/fneur.2017.00655","volume":"8","author":"P Sarchielli","year":"2017","unstructured":"Sarchielli P, Romoli M, Corbelli I et al (2017) Stopping Onabotulinum treatment after the first two cycles might not be justified: results of a real-life monocentric prospective study in chronic migraine. Front Neurol 8:655","journal-title":"Front Neurol"},{"key":"921_CR39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-016-0676-z","volume":"17","author":"M Vikelis","year":"2016","unstructured":"Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Mitsikostas DD (2016) Onabotulinumtoxin-a treatment in Greek patients with chronic migraine. J Headache Pain 17:84","journal-title":"J Headache Pain"},{"key":"921_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.toxicon.2017.08.026","volume":"147","author":"Cristina Tassorelli","year":"2018","unstructured":"Tassorelli C, Sances G, Avenali M, et al (2018) Botulinum toxin for chronic migraine: clinical trials and technical aspects. Toxicon 147:111\u2013115","journal-title":"Toxicon"},{"key":"921_CR41","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1177\/0333102417724150","volume":"37","author":"M Matharu","year":"2017","unstructured":"Matharu M, Pascual J, Nilsson RI et al (2017) Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia 37:1384\u20131397","journal-title":"Cephalalgia"},{"key":"921_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1526-4610.2010.01796.x","volume":"51","author":"RK Cady","year":"2011","unstructured":"Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU (2011) A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 51:21\u201332","journal-title":"Headache"},{"key":"921_CR43","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1111\/j.1526-4610.2009.01566.x","volume":"49","author":"NT Mathew","year":"2009","unstructured":"Mathew NT, Jaffri SF (2009) A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache 49:1466\u20131478","journal-title":"Headache"},{"key":"921_CR44","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40265-018-0894-6","volume":"78","author":"JE Frampton","year":"2018","unstructured":"Frampton JE, Silberstein S (2018) OnabotulinumtoxinA: a review in the prevention of chronic migraine. Drugs 78:589\u2013600","journal-title":"Drugs"},{"key":"921_CR45","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1177\/0333102416660549","volume":"37","author":"C Tassorelli","year":"2017","unstructured":"Tassorelli C, Jensen R, Allena M et al (2017) The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: a controlled multicentre study. Cephalalgia 37:1115\u20131125","journal-title":"Cephalalgia"},{"key":"921_CR46","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1177\/0333102412451363","volume":"32","author":"SB Munksgaard","year":"2012","unstructured":"Munksgaard SB, Bendtsen L, Jensen RH (2012) Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: a comparison of two consecutive treatment methods in an open-label design. Cephalalgia 32:834\u2013844","journal-title":"Cephalalgia"},{"key":"921_CR47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/2042098616653390","volume":"7","author":"ML Westergaard","year":"2016","unstructured":"Westergaard ML, Munksgaard SB, Bendtsen L, Jensen RH (2016) Medication-overuse headache: a perspective review. Ther Adv Drug Saf 7:147\u2013158","journal-title":"Ther Adv Drug Saf"},{"key":"921_CR48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.toxicon.2018.03.011","volume":"147","author":"Mark W. Green","year":"2018","unstructured":"Green MW, Rothrock JF (2018) An academic debate: OnabotulinumtoxinA for chronic migraine: PREEMPT-derived vs \u201ccustomized\u201d dosing\/injection paradigm. Toxicon 147:116\u2013119","journal-title":"Toxicon"},{"key":"921_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149\u2013158","journal-title":"Pain"},{"key":"921_CR50","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s10194-017-0773-7","volume":"18","author":"C Tassorelli","year":"2017","unstructured":"Tassorelli C, Aguggia M, De TM et al (2017) Onabotulinumtoxin a for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. J Headache Pain 18:66\u201377","journal-title":"J Headache Pain"},{"key":"921_CR51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI et al (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 18:101\u20130787","journal-title":"J Headache Pain"},{"key":"921_CR52","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","volume":"87","author":"MT Minen","year":"2016","unstructured":"Minen MT, Begasse De DO, Kroon Van DA et al (2016) Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 87:741\u2013749","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"921_CR53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20:22\u201333","journal-title":"J Manag Care Pharm"},{"issue":"Suppl 1","key":"921_CR54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10072-014-1741-5","volume":"35","author":"M Ruggeri","year":"2014","unstructured":"Ruggeri M (2014) The cost effectiveness of Botox in Italian patients with chronic migraine. Neurol Sci 35(Suppl 1):45\u201347","journal-title":"Neurol Sci"},{"key":"921_CR55","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/head.12456","volume":"54","author":"JF Rothrock","year":"2014","unstructured":"Rothrock JF, Bloudek LM, Houle TT, Andress-Rothrock D, Varon SF (2014) Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine. Headache 54:1565\u20131573","journal-title":"Headache"},{"key":"921_CR56","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3111\/13696998.2013.802694","volume":"16","author":"AJ Batty","year":"2013","unstructured":"Batty AJ, Hansen RN, Bloudek LM et al (2013) The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ 16:877\u2013887","journal-title":"J Med Econ"},{"issue":"8","key":"921_CR57","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/ene.13657","volume":"25","author":"A. P. Andreou","year":"2018","unstructured":"Andreou AP, Trimboli M, Al-Kaisy A et al (2018) Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for health and care excellence UK technology appraisal. Eur J Neurol 25:1069\u20131083","journal-title":"European Journal of Neurology"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-018-0921-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-018-0921-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-018-0921-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T15:51:49Z","timestamp":1662133909000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-018-0921-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,26]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["921"],"URL":"https:\/\/doi.org\/10.1186\/s10194-018-0921-8","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,26]]},"assertion":[{"value":"22 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LB: Scientific advisory board for Novartis, Allergan and Biogen, principal investigator for Biogen and lectures for Allergan, Novartis and Teva. SS: Scientific advisory board for Allergan, Bayer Healthcare, Medtronic. MA: Personal fees from Alder BioPharmaceuticals, Allergan, Amgen, Alder, Eli Lilly, Novartis and Teva. Participated in clinical trials as the principal investigator for Alder ALD403-CLIN-011 (Phase 3b), Amgen 20,120,178 (Phase 2), 20,120,295 (Phase 2), 20,130,255 (OLE), 20,120,297 (Phase 3), GM-11 gamma-Core-R trials, Novartis CAMG334a2301 (Phase 3b), Amgen PAC1 20,150,308 (Phase 2a), Teva TV48125-CNS-30068 (Phase 3). Serves as associated editor of Cephalalgia, co-editor of the Journal of Headache and Pain.DM: Scientific advisory board for Novartis, Eli Lilly, Sanofi-Genzyme and Teva. Principal investigator for Biogen, Cephaly, Genesis Pharma, Merck-Serono, Merz, Novartis and Teva. Has received honoraria for lecturing from Allergan, Amgen, Cephaly, Biogen, Genesis Pharma, Novartis, Rosche, Sanofi-Genzyme, Teva. FA: Consultant for Novartis, Allergan, Eneura and Electrocore (honorarium paid to the British Association for the Study of Headache and the Migraine Trust). PPR: Consultant and speaker for Allergan, Almirall, Chiesi, Eli Lilly, Novartis and Teva. Her research group has received research grants from Allergan and Novartis and has received funding for clinical trials from Alder, Boeringher Ingelheim, MSD, Electrocore, Eli Lilly, Janssen Cilag, Novartis and Teva. PM: Scientific Advisory Board for Allergan, Amgen, Electrocore, Eli Lilly, Novartis, Springer HealthCare, Teva.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"91"}}